Genetic panel for canine solid tumors

• Grant number: 17/01016-9
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: July 01, 2018
• End date: September 30, 2019
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Preventive Veterinary Medicine
• Principal Investigator: Claudia Filoni
• Grantee: Claudia Filoni
• Company: Labfauna Diagnóstico Veterinário Laboratorial Ltda
• City: São Paulo
• Associated researchers: Edison Luiz Durigon
• Associated scholarship(s): 18/18111-7 - Development of a rapid metagenomic test for simultaneous detection of multiple pathogens, BP.TT; 18/12835-3 - Development of a rapid metagenomic test for simultaneous detection of multiple pathogens, BP.PIPE

Abstract

Veterinary Oncology is expanding. Domestic pets have a higher life expectancy, they receive better veterinary assistance and new anticancer drugs are available. Cito and histopathological analyses are routinely performed in cases of solid tumors clinical suspicions e less frequently immunohistochemical analyses. Despite their fundamental importance, sophisticated diagnostic approaches are requested for genetic and physiopathological characterizations of tumors, thus permitting rationale choices of treatments and drugs. In this context, we propose to develop a Genetic Panel for Canine Solid Tumors as concept proof, using advanced genetic sequencing techniques in a limited number of solid tumors samples. We will identify alterations in selected genes aiming to provide a rationale for therapy choice. Given that, our proposal is to develop a genetic panel, using next-generation sequencing (NGS) to facilitate the choice of adequate therapy in an individual base for a number of solid tumors in dogs. We aim to identify relevant alterations in BRCA1, BRCA2, BRAF and KIT genes in cases of mammary tumors (BRCA1, BRCA2); urothelial, prostatic and pulmonary carcinomas, melanomas, melanocytomas, gliomas, peripheral nerve sheath tumor (BRAF); mast cell tumors, gastrointestinal stromal tumors, leukemias, lymphomas, anal sac adenocarcinomas, thyroid carcinomas, haemangiosarcomas, seminomas, interstitial and granulosa cell tumors (KIT). DNA from a limited number of formalin-fixed paraffin-embedded (FFPE) samples will be sequenced by NGS and aligned with the canine genome reference sequence. Genetic variant calling will be performed. (AU)